MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals
Abstract
Background: One of the diagnostic imaging hallmarks of MS is the uptake of IV administered contrast material in new lesions in the brain, signaling blood–brain barrier breakdown and active inflammation. Many clinical drug trials are designed based on the assumption that lesion enhancement on MRI remains visible on average for 1 month. For practical reasons, few serial MRI studies of patients with MS have been performed at intervals shorter than 4 weeks.
Methods: The authors performed a year-long longitudinal study in 26 patients with relapsing-remitting MS (RRMS), which comprised an initial phase of MRI follow-up at weekly intervals for 8 weeks, followed by imaging every other week for another 16 weeks, and monthly thereafter. They present a quantitative analysis (using a supervised interactive thresholding procedure) of new enhancing lesions appearing during the first 6 weeks in this cohort and evaluated from the time of first detection until enhancement was no longer seen.
Results: The average duration of Gd-DTPA enhancement in individual new lesions was 3.07 weeks (median, 2 weeks). Significant correlations were demonstrated between the duration of contrast enhancement or initial growth rates and lesion volumes. Different lesions in the same patient appeared to develop largely independent of each other and demonstrated a large range in the duration of enhancement during the acute phase of their evolution.
Conclusions: The average duration of blood–brain barrier impairment in RRMS is shorter than earlier estimates. Early lesion growth parameters may predict final lesion size. Within-patient heterogeneity of lesion evolution suggests that individual lesions develop independently.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Miller DH, Rudge P, Johnson G. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain . 1988; 111: 927–939.
2.
Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium DTPA enhancement. Neurology . 1990; 40: 229–235.
3.
Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol . 1991; 29: 548–555.
4.
Guttmann CRG, Ahn S, Hsu L, Kikinis R, Jolesz FA. The evolution of multiple sclerosis on serial MR. AJNR Am J Neuroradiol . 1995; 16: 1481–1491.
5.
Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol . 1991; 29: 53–62.
6.
Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology . 1992; 42: 60–63.
7.
McFarland HF, Frank JA, Albert PS, et al. Using gadolinium enhanced imaging to monitor disease activity in multiple sclerosis. Ann Neurol . 1992; 32: 758–766.
8.
Capra R, Marciano N, Vignolo LA, Chiesa A, Gasparotti R. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. Arch Neurol . 1992; 49: 687–689.
9.
Barkhof F, Scheltens P, Frequin STFM, Nauta JJP, Tas MW, Valk J. Relapsing-remitting multiple sclerosis: sequential enhanced MR imagings vs clinical findings in determining disease activity. AJR Am J Roentgenol . 1992; 159: 1041–1047.
10.
Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol . 1993; 33: 480–489.
11.
Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry . 1996; 60: 15–19.
12.
Hein J, van Waesberghe M, Marianne A, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol . 1998; 19: 675–683.
13.
Hawkins P, Munro PMG, Mackenzie F, Kesselring J, Tofts PS, du Boulay EPG H. Duration and selectivity of blood-brain-barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain . 1990; 113: 365–378.
14.
Hawkins CP, MacKenzie F, Tofts P, Du Boulay EPGH, McDonald WI. Patterns of blood brain barrier breakdown in inflammatory demyelination. Brain . 1991; 114: 801–810.
15.
Lai M, Hodgson T, Gawne-Cain M, et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry . 1996; 60: 339–341.
16.
Rocca MA, Cercignani M, Iannucci G, Comi G, Filippi M. Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology . 2000; 26: 882–884.
17.
Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology . 1994; 44: 2120–2124.
18.
Hohol MJ, Guttmann CRG, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol . 1997; 54: 1018–1025.
19.
Weiner HL, Guttmann CRG, Khoury SJ, et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol . 2000; 104: 164–173.
20.
Guttmann CRG, Kikinis R, Anderson MC, et al. Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility. JMRI . 1999; 9: 509–518.
21.
Drayer BP. Magnetic resonance imaging of multiple sclerosis. Barrow Neurol Institute Q . 1987; 169: 117–122.
22.
Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodrigez . Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases of autopsy. Radiology . 1991; 180: 467–474.
23.
Powell T, Sussman JG, Davies-Jones GA. MR Imaging in acute multiple sclerosis: ring-like appearance in plaques suggesting the presence of paramagnetic free radicals. AJNR Am J Neuroradiol . 1992; 13: 1544–1546.
24.
Cline HE, Lorensen WE, Kikinis R, Jolesz FA. Three-dimensional segmentation of MR images of the head using probability and connectivity. J Comput Assist Tomogr . 1990; 14: 1037–1045.
25.
Filippi M, et al. Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis. A comparison of techniques. Brain . 1995; 118: 1593–1600.
26.
McDonald WI, Barnes D. Lessons from magnetic resonance imaging in multiple sclerosis. Trends . 1989; 12: 376–379.
27.
McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol . 1992; 18: 319–334.
28.
Miller DH, Barkhof F, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry . 1991; 54: 683–688.
29.
Namer IJ, Steibel J, Piddlesden SJ, et al. Magnetic resonance imaging of antibody–mediated demyelinating experimental allergy encephalomyelitis. J Neuroimmunol . 1994; 54: 41–50.
30.
Isaac C, Li DK, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology . 1988; 38: 1511–1515.
31.
Willoughby EW, Grochowski E, Li DKB, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing remitting patients. Ann Neurol . 1989; 25: 43–49.
32.
Tofts PS, Kermode AG. Measurement of the blood brain barrier permeability and leakage space using dynamic MR imaging. Fundamental concepts. Magn Reson Med . 1991; 17: 357–367.
33.
Tofts PS. Optimal detection of blood brain barrier defects with gadolinium-DTPA MRI–the influences of delayed images and optimized repetition time. MRI . 1996; 14: 373–380.
34.
Grossman RI, Gonzalez-Scarano F, Atals SW, Galetta S, Silberberg DH. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology . 1986; 161: 721–725.
35.
Campi A, Filippi M, Comi G, Scotti G, Gerevini S, Dousset V. Magnetization transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis. Neuroradiology . 1996; 38: 115–119.
36.
He J, Grossman RI, Ge Y, Mannon LJ. Enhancing patterns in multiple sclerosis: evolution and persistence. AJNR Am J Neuroradiol . 2001; 22: 664–669.
37.
Petrella JR, Grossman RI, McGowan JC, Campbell G, Cohen JA. Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. AJNR Am J Neuroradiol . 1996; 17: 1041–1049.
38.
Hiele JF, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol . 1995; 16: 69–77.
39.
Larsson HB, Frederiksen J, Petersen J, et al. Assessment of demyelination, edema, and gliosis by in vivo determination of T1 and T2 in the brain of patients with acute attack of multiple sclerosis. MRM . 1989; 11: 337–348.
40.
Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol . 1997; 42: 783–793.
41.
Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced lesions MR imaging. Radiology . 1988; 169: 117–122.
42.
Broman T. Blood-brain barrier damage in multiple sclerosis: supra vital test observations. Acta Neurol Scand . 1964; 49: 21–24.
43.
Prineas JW, Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology . 1978; 28: 68–75.
44.
Losseff NA, Miller DH, Kidd D, Thompson AJ. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis—preliminary results. Mult Scler . 2001; 7: 23–25.
45.
Tubridy N, Coles AJ, Molyneux P, et al. Secondary progressive multiple sclerosis: the relationship between short term MRI activity and clinical features. Brain . 1998; 121: 225–231.
46.
Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet . 1999; 353: 964–969.
47.
Miki Y, Grossman RI, Udupa JK, et al. Computer-assisted quantitation of enhancing lesions in multiple sclerosis: correlation with clinical classification. AJNR Am J Neuroradiol . 1997; 18: 705–710.
Information & Authors
Information
Published In
Copyright
© 2003.
Publication History
Received: December 10, 2001
Accepted: October 17, 2002
Published online: February 25, 2003
Published in print: February 25, 2003
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Magnetic resonance imaging prognostic factors for survival and relapse in dogs with meningoencephalitis of unknown origin, Frontiers in Veterinary Science, 11, (2024).https://doi.org/10.3389/fvets.2024.1370882
- Typical and Emerging Diagnostic MRI Features in Multiple Sclerosis, Canadian Association of Radiologists Journal, (2024).https://doi.org/10.1177/08465371241261847
- Inhomogeneous magnetization transfer (ihMT) imaging reveals variable recovery profiles of active MS lesions according to size and localization, Imaging Neuroscience, 2, (1-20), (2024).https://doi.org/10.1162/imag_a_00235
- Treatment Monitoring in Multiple Sclerosis — Efficacy and Safety, Neuroimaging Clinics of North America, 34, 3, (439-452), (2024).https://doi.org/10.1016/j.nic.2024.03.009
- Multiple Sclerosis: An Emergency Medicine-Focused Narrative Review, The Journal of Emergency Medicine, 66, 4, (e441-e456), (2024).https://doi.org/10.1016/j.jemermed.2023.12.003
- ACR Appropriateness Criteria® Orbital Imaging and Vision Loss-Child, Journal of the American College of Radiology, 21, 6, (S219-S236), (2024).https://doi.org/10.1016/j.jacr.2024.02.023
- T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis, Neuroradiology, 66, 10, (1709-1719), (2024).https://doi.org/10.1007/s00234-024-03400-4
- Demyelinating Diseases of the CNS (Brain and Spine), Diseases of the Brain, Head and Neck, Spine 2024-2027, (189-202), (2024).https://doi.org/10.1007/978-3-031-50675-8_13
- New Enhancing MRI Lesions Associate with IL-17, Neutrophil Degranulation and Integrin Microparticles: Multi-Omics Combined with Frequent MRI in Multiple Sclerosis, Biomedicines, 11, 12, (3170), (2023).https://doi.org/10.3390/biomedicines11123170
- A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1265354
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.